Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Epigenetic Modifiers as Radiosensitizers for SHHa Medulloblastoma

EF 2021-22

Résumé
Medulloblastomas of the SHHa subtype have poor prognoses and do not respond well to new targetted chemotherapeutics for SHH medulloblastoma. Enrichment for pathways related to DNA repair, the cell cycle, and chromatin modifications, as well as enrichment for mutations in some chromatin modifiers, suggest that epigenetic priming could be used to radiosensitize SHHa tumours. This project seeks to identify epigenetic modifiers that have radiosensitizing activity in SHHa medulloblastoma through a drug screen plus exposure of the cells to a sublethal dose of radiation. This will be followed by an evaluation of any active compounds' effects on cell proliferation, clonogenic capacity, and gene expression.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
480741
Name
Liedtke Elisabeth P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Epigenetic Modifiers as Radiosensitizers for SHHa Medulloblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Epigenetics; Medulloblastoma; Radiosensitizers
Abstract
Medulloblastomas of the SHHa subtype have poor prognoses and do not respond well to new targetted chemotherapeutics for SHH medulloblastoma. Enrichment for pathways related to DNA repair, the cell cycle, and chromatin modifications, as well as enrichment for mutations in some chromatin modifiers, suggest that epigenetic priming could be used to radiosensitize SHHa tumours. This project seeks to identify epigenetic modifiers that have radiosensitizing activity in SHHa medulloblastoma through a drug screen plus exposure of the cells to a sublethal dose of radiation. This will be followed by an evaluation of any active compounds' effects on cell proliferation, clonogenic capacity, and gene expression.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liedtke, Elisabeth P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~